Perkin Elmer Updates Q2 Outlook
Perkin Elmer has today revised their outlook for Q2, announcing that they expect growth of approximately 12% for the second quarter ended July 5, 2020.
The strong revenue growth was driven by better-than-expected demand for solutions aimed at COVID-19 testing needs across the globe. Demand for the Company’s RT-PCR and serology tests, RNA extraction systems and kits and automated liquid handling instrumentation was particularly robust. In total, COVID-19 related solutions contributed approximately $190 million of revenue in Q2.
Perkin Elmer will release full financials for Q2 on July 28th.